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Abstract
We have recently identified and validated the prostate cancer antigen Tomoregulin as a target for the radioimmuno-
therapy for prostate cancer. Here, we provide evidence that Tomoregulin is an internalizing antigen and a potential
target for immunotoxins. First, the cell surface localization of Tomoregulin was confirmed by flow cytometry, and its
expression levels were determined by whole-cell binding assays. Second, laser scanning confocal microscopy re-
vealed Tomoregulin internalization into the cytoplasm on antibody binding at 37°C. The internalized Tomoregulin
was found to colocalize with acidic vesicles. Third, internalization kinetics assays using 125I-labeled anti-Tomoregulin
mouse monoclonal antibody 2H8 demonstrated that the amount of internalized antigen–antibody complexes in-
creased with time and reached ∼25% of the total surface antigen after 60 to 90 minutes. Because 2H8 is capable
of binding to Tomoregulin on the cell surface and can be internalized, we finally evaluated 2H8 as a means of target-
ing toxic payloads to prostate cancer cells. 2H8 was coupled to the cytotoxin saporin through a secondary antibody
(Mab-ZAP) in indirect immunotoxin assays. Cell killing occurred on Tomoregulin-positive cells (Clone69) at the
immunotoxin concentrations not affecting the Tomoregulin-negative cells (PC-3). In contrast to 2H8, the control
antibody (mouse anti–c-Myc antibody 9E10) had no effect on cells in the presence of Mab-ZAP. Thus, Tomoregulin
internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells, and Tomoregulin-mediated
delivery of immunotoxin has potential as a prostate cancer therapy.
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Introduction
Tomoregulin (also named TMEFF2, TENB2, TPEF, and HPP1) is
a type I transmembrane protein with a short cytoplasmic tail; it con-
tains one epidermal growth factor–like motif and two follistatin do-
mains in its extracellular region [1–5]. This protein is selectively
expressed in the prostate and brain but not expressed in other normal
tissues [2,3]. Due to its restricted expression profile in normal tissues
and its increased expression in prostate cancer, Tomoregulin has re-
ceived considerable attention as a promising immunotherapeutic
target for cancer therapy [6–8]. Recently, we have demonstrated
Tomoregulin as a validated target for the radioimmunotherapy for
prostate cancer [7].
Besides radioimmunotherapy, immunotoxins represent a novel
therapeutic option for treating cancer patients [9,10]. Immunotoxins
are tumor-targeting antibodies or growth factors linked to poisonous
proteins (toxins) produced by bacteria or plants. Various toxins are
fused to antibodies through genetic engineering or chemical conju-
gation. Bacterial toxins used in cancer indications include diphtheria
toxin and Pseudomonas exotoxin, and they are well suited to form-
ing recombinant fusion proteins. Plant toxins such as ricin, saporin,
gelonin, and pokeweed antiviral protein are generally conjugated to
ligands by disulfide bond chemistry.
The toxin used in this study is saporin. Saporin is found in seeds
and leaves of the plant Saponaria officinalis and belongs to class I
ribosome-inactivating proteins [11]. Saporin functions as an RNA
N-glycosidase and inhibits protein synthesis by cleaving one specific
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adenine base from ribosomal RNA and inducing irreversible ribo-
somal damage.
In an immunotoxin, the antibody component allows for selective
delivery of a toxin to the surface of cells bearing the target antigen.
On antigen–antibody binding, the immunotoxin is internalized by
the target cells, and the enzymatic fragment of the toxin translocates
to the cytosol. The toxin fragment often induces irreversible ribosomal
damage, inhibits protein synthesis, and causes cell death. Thus, for an
immunotoxin to work, the target must be an internalizing antigen
(i.e., located on the cell surface and internalized into cytoplasm).
The purpose of this study was to evaluate whether Tomoregulin pro-
tein is an internalizing antigen and whether the Tomoregulin-specific
antibody 2H8 can be used as a means of targeting saporin-containing
immunotoxins to prostate cancer cells. Here, we demonstrate by con-
focal microscopy that the cell surface Tomoregulin protein is internal-
ized into vesicle structures in the cytoplasm on 2H8 binding. Moreover,
Tomoregulin internalization confers selective cytotoxicity of immuno-
toxins on prostate cancer cells. Thus, Tomoregulin-mediated immuno-
toxin targeting has potential as a prostate cancer therapy.
Materials and Methods
Reagents
The anti-Tomoregulin murine monoclonal antibody 2H8 (IgG1/k)
and the control antibody mouse IgG1 clone G18-145 were described
[7]. 2H8 was custom-labeled using 125I by Amersham Biosciences
(Woburn, MA) with a specific activity of 1260 to 1920 Ci/mmol.
The immunotoxin Mab-ZAP [12], a goat antimouse IgG antibody
covalently linked to saporin, was obtained from Advanced Targeting
Systems, San Diego, CA.
Cell Culture
Both PC-3 and Clone36 cell lines were previously described [7].
Like Clone36, the Clone69 cell line was generated by stably trans-
fecting PC-3 cells with pcDNA3.1-Tomoregulin. These cells were
maintained in RPMI-1640 medium, supplemented with 10% FBS
and 400 μg/ml G418.
Flow Cytometry
One million live cells in 100 μl of PBS buffer were incubated for
1 hour at 4°C with 2H8 or mouse IgG1 (2 μg per tube). Excess anti-
body was washed away with 1 ml of PBS followed by centrifugation,
and cells were resuspended and incubated for 45 minutes at 4°C in
100 μl of PBS containing 1 μg of fluorescein isothiocyanate (FITC)–
labeled horse antimouse IgG (H + L) antibody (Vector Laboratories
Inc., South San Francisco, CA). After washing, cells were resuspended
in 3 ml of PBS containing 5 μl of propidium iodide at 1 μg/ml
(Molecular Probes, Eugene, OR). Fluorescence intensity was measured
using the FACS-Calibur (Becton Dickinson, Palo Alto, CA) and ana-
lyzed for at least 10,000 events.
Whole-Cell Binding Assays
Cells (2–5 × 104) were incubated with 125I-2H8 at concentra-
tions ranging from 3.9 pM to 8 nM in 100 μl of binding buffer
(RPMI-1640 medium, 50 mM HEPES, 0.1% BSA, 5 mM MgCl2,
and 100 μg/ml bactracin) on ice for 3 hours to reach equilibrium.
Nonspecific binding was assessed by performing a second set of reac-
tions in the presence of 10 μM cold 2H8. The reactions were termi-
nated by centrifugation at 1300g for 10 minutes at 4°C after 800 μl of
ice-cold binding buffer was added to each tube. The cell pellets were
washed once in ice-cold binding buffer. The bound 125I-2H8 was de-
termined by counting the cell pellet for 1 minute in a Titertek gamma
counter (Titertek Instruments Inc., Hillsville, AL). Specific binding
was derived by subtracting nonspecific binding from total binding.
Data were analyzed using a computer software (PRISM; GraphPad
Software, Inc., San Diego, CA). The number of Tomoregulin (Bmax)
and the affinity of 125I-2H8 binding (K d) were determined by data
fitting to the equation using nonlinear regression model [13].
Internalization Assays and Confocal Microscopy
Cells were grown in RPMI-1640 medium with 10% FBS on eight-
well glass chamber slides (Nalgene Nunc International, Naperville,
IL) overnight. The growth medium was then replaced with a medium
containing primary antibody 2H8 (2 μg/well) at 4°C for 2 hours.
Cells were washed three times with cold PBS. The secondary anti-
body AlexaFluor 488–labeled goat antimouse IgG (H + L) antibody
(Molecular Probes) was then added at a dilution of 1:500 and in-
cubated at 4 or 37°C for 3 hours followed by three washes in cold
PBS. Plasma membranes were stained using CM-DiI dye (Molecular
Probes). Cells were washed three times with PBS, fixed using 5%
paraformaldehyde in PBS for 10 minutes at room temperature, and
washed two additional times using PBS. Slides were coverslipped using
Fluorescent Mounting Medium (DakoCytomation, Carpinteria, CA).
Confocal images of the double-labeled cells were captured using
a LSM5 Pascal confocal laser scanning microscope equipped with a
PlanNeofluar 63×/1.25 oil objective (Carl Zeiss AG, Jena, Germany).
Slides were scanned using the multitrack mode (red and green chan-
nels) to avoid bleed through. Images represent a stack of 20 focal planes
(1 μm apart). Single frames from representative stacks were exported
into Adobe Photoshop 7.0 and saved as JPEG files.
LysoTracker Staining
The LysoTracker Red DND-99 (Molecular Probes) is a red fluo-
rescent acid tropic probe for labeling and tracking acidic organelles in
live cells. Cells were incubated with 50 to 75 nM LysoTracker Red
DND-99 for 1 hour at 37°C, according to the manufacturer’s recom-
mendation, before performing the internalization assays without
CM-DiI dye.
Magic Red Staining
Magic Red (RR)2 (Immunochemistry Technologies, LLC, Blooming-
ton, MN) is a nonfluorescent substrate, which can be converted by
cathepsin B into the product cresyl violet with red fluorescence at
592/628 nm. Magic Red (RR)2 easily penetrates the plasma mem-
brane and the membranes of cellular organelles, and it can be used
to detect active cathepsin B within live cells. Cells were incubated
with Magic Red (RR)2 at 0.25× working solution concentration
for 1 hour at 37°C according to the manufacturer’s recommendation
before performing the internalization assays without CM-DiI dye.
Quantitative Internalization Assay
Cells were incubated in 200 μl of binding buffer for 3 hours on
ice with 4 nM 125I-2H8 alone or in the presence of 100-fold excess
of unlabeled 2H8 to determine nonspecific binding. After surface
binding of 125I-2H8 reached equilibrium, the cell pellet was washed
twice with ice-cold binding buffer and resuspended in 200 μl of the
same buffer. Incubation temperature was shifted to 37°C to allow
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Tomoregulin internalization. At each incubation time (0–90 min-
utes), each set of samples was processed. The dissociated 125I-2H8
present in the culture medium was collected (first cell supernatant)
by centrifuging at 1300g for 5 minutes at 4°C. The cell pellets were
washed twice with acidic PBS (PBS + 1% glucose, pH ∼ 1.0 by add-
ing HCl) that removed the surface-bound 2H8 and separated it from
the internalized 2H8 by a further centrifugation. Two acid wash
supernatants were combined and saved. The percentage of 2H8 dis-
tributed as dissociated, surface-bound, and internalized portions was
determined from the radioactivity counts in the first cell supernatant,
acid supernatant, and the cell pellet, respectively.
Formation of Antibody–Immunotoxin Complex
The antibody 2H8 or the control mouse anti–c-Myc antibody 9E10
(Roche Molecular Biochemicals, Basel, Switzerland) at 10 μg/ml was
preincubated under shaking with the same amount (1:1) or fivefold
excess of (1:5) of Mab-ZAP in PBS for 2 hours at room temperature.
The mixtures were sterile-filtered with Millex-GV, 0.22-μm poly-
vinylidene difluoride membrane (Millipore, Billerica, MA) and then
used for half-maximal growth inhibition (IC50) determination in the
cell proliferation assays.
Cell Proliferation Assay
Cells were seeded at 5 × 103 cells per well in 96-well plates and
allowed to adhere for 24 hours. Then, fresh growth medium contain-
ing antibody–immunotoxin complexes was added. On exposure of
the cells to immune complexes for 4, 7, 24, or 48 hours, the medium
was removed, the cells were washed twice with PBS, and fresh growth
medium without immune complexes was added. After a total in-
cubation time of 72 hours, the cells were fixed with glutaraldehyde,
stained with crystal violet, and the absorbance was recorded at 595 nm
using an ELISA reader (V Max, Molecular Devices, Sunnyvale, CA).
All measurements were performed in quadruplicate. The values were
normalized to the absorbance of PBS-treated cells (= 100%), and
the absorbance of a reference plate that was fixed at the time point
of treatment (= 0%). Half-maximal growth inhibition was determined
as antibody concentration required to achieve 50% inhibition of cel-
lular growth.
Results
Tomoregulin Protein Is Expressed on the Cell Surface
The cellular localization of Tomoregulin protein was revealed by flow
cytometry. Live cells were incubated at 4°C with anti-Tomoregulin
Mab 2H8 [7] and detected using FITC-labeled horse antimouse
IgG (H + L) antibody. A mouse IgG1 isotype control was used for
comparison. Dead cells (stained with propidium iodide) were ex-
cluded, and only live cells were gated for measuring Tomoregulin-
specific signal intensity. As shown in Figure 1, 2H8 bound strongly
to intact cells of both Clone36 (Geo Means = 24.66; Figure 1B) and
Clone69 (Geo Means = 65.3; Figure 1C ), two stably transfected cell
lines derived from the human prostate cancer cell line PC-3 expres-
sing recombinant Tomoregulin protein. In contrast, there was no
specific binding of 2H8 to PC-3 cells (Figure 1A) in which both
Tomoregulin mRNA and protein are not detectable [7]. These data
point to the cell surface localization of Tomoregulin on Clone36 and
Clone69 cells. Moreover, the significant difference in FITC fluores-
cence intensity (i.e., FL1-H in the x-axis) between these two cell lines
(24.66 vs 65.3) indicates that Tomoregulin protein expression on
Clone69 is much higher than that on Clone36.
Sites of Tomoregulin per Cell Are Determined by Whole
Cell Binding Assays
We performed equilibrium binding studies on intact cells of PC-3,
Clone36, and Clone69 using various concentrations of radiolabeled
antibody 125I-2H8. Figure 2 shows dose–response plots obtained
after correction for nonspecific binding. The specific binding of
125I-2H8 to Tomoregulin on Clone36 (Figure 2B) and Clone69
(Figure 2C ) cells was dose-dependent and reached saturation at ap-
proximately 4 nM 125I-2H8. Under the same assay conditions, little
or no specific binding was detected on PC-3 cells (Figure 2A).
The total Tomoregulin sites (Bmax) and equilibrium dissocia-
tion constant (K d) were generated by data fitting to the equation
Figure 1. Detection of cell surface Tomoregulin protein by flow
cytometry. PC-3 (A), Clone36 (B), and Clone69 (C) cells were
stained with anti-Tomoregulin antibody 2H8 (green) or isotype
control mouse IgG1 (blue). x Axis represents mean fluorescence
intensity (i.e., FL 1-H), indicating the level of antigen expression.
y Axis is relative cell number (i.e., Counts). The ratio of Geo Means
for 2H8-bound to mIgG-bound is indicated under the name of each
cell line.
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of nonlinear regression model using PRISM (GraphPad Software,
Inc.). The Tomoregulin molecules expressed on the cell surface of
Clone36 and Clone69 were determined as 0.32 × 106 and 0.65 ×
106 per cell, respectively, assuming bivalent interaction of 2H8 with
cell surface Tomoregulin. Twice as many Tomoregulin sites were de-
tected on Clone69 as on Clone36, and this result is consistent with
the flow cytometry data shown in Figure 1. The binding affinity (K d)
of 2H8 to Tomoregulin on Clone36 and Clone69, 0.75 and 1.55 nM,
respectively, is also similar to the K d value (1 nM) obtained by
BIAcore analysis for 2H8 binding to the recombinant Tomoregulin
protein [7].
The Cell Surface Tomoregulin Is Internalized on 2H8 Binding
To test whether Tomoregulin is an internalizing antigen, a pre-
requisite for immunotoxin therapy, a live-cell internalization assay
was developed (see Materials and Methods section). After antibody
binding, 2H8/Tomoregulin complexes were visualized by a Alexa-
Fluor 488–labeled goat antimouse–IgG antibody (green). Images by
confocal microscopy demonstrated that Tomoregulin protein is local-
ized to the plasma membrane of Clone36 cells at 4°C, a nonpermissive
temperature for internalization (Figure 3A). At 37°C, the permissive
temperature for internalization, Tomoregulin was internalized into
vesicle structures of cytoplasm on 2H8 binding, moving from the
cell membrane to the perinuclear region, most likely through endo-
cytosis (Figure 3B). These data clearly verified that Tomoregulin is
an internalizing antigen. Hence, Tomoregulin-targeting immunotoxin
can be considered as a treatment modality for Tomoregulin-positive
prostate cancer.
The Internalized Tomoregulin Is Colocalized with Acidic
Vesicles in Living Cells
The receptor-mediated endocytosis pathway [14] involves multi-
ple acidic organelles: early endosomes (pH 5.9–6.0), late endosomes
(pH 5.0–6.0), and lysosomes (pH 5.0–5.5). Confocal images re-
vealed, at 4°C (Figure 4, A–C ), Tomoregulin stays at the cell surface
(Figure 4A), whereas acidic organelles are found intracellularly in
vesicle structures (Figure 4B). No colocalization was observed (Fig-
ure 4C ). At 37°C (Figure 4, D–F ), Tomoregulin is internalized into
the cytoplasm (Figure 4D), and the internalized Tomoregulin (green)
appears to colocalize with acidic vesicles (red), producing the yellow
patches in Figure 4F.
Lysosomes are considered the final stop of endocytosis. Receptor
internalization through endocytosis leads to either receptor recycling
or receptor degradation through lysosomal proteolysis. Because one
of the major endosomal/lysosomal proteases is cathepsin B, we also
stained sites of active cathepsin B in living cells using Magic Red
(RR)2, a fluorogenic substrate for cathepsin B. The internalized
Tomoregulin appeared to colocalize with sites of active cathepsin B
(data not shown).
These results suggest that the internalized complex goes to cytoplas-
mic acidic vesicles in living cells, which is also colocalized with lyso-
somal active cathepsin B sites.
Tomoregulin Internalization Is Time-Dependent
To determine the amount and kinetics of Tomoregulin internaliza-
tion on antibody binding, we performed quantitative analyzes using
125I-2H8. As shown in Figure 5A, switching incubation temperature
from 4 to 37°C facilitated the dissociation of 125I-2H8 from cells and,
at the same time, triggered the internalization of Tomoregulin/2H8
complex. The percentages of internalized 125I-2H8 increased with
time at 37°C incubation, whereas the amount of cell surface bound
125I-2H8 decreased over 90 minutes (Figure 5A). Tomoregulin–125I-
2H8 internalization was clearly detectable as early as 5 minutes after
shifting to 37°C and reached a maximum of 27% at 60 minutes for
Clone69 cells (Figure 5B). For Clone36 cells, the maximal 125I-2H8
internalization during a 120-minute incubation at 37°C was 25%
(data not shown). These values (25–27% internalization) are similar
to the values reported for antibody-induced HER-2 internalization in
the literature [15].
On the basis of the data collected, the amount of internalized
Tomoregulin per cell in Clone36 and Clone69 can be calculated
(25% of 0.32–0.65 × 106). Because the average volume of a mamma-
lian cell is approximately 10−15 L, the internalized Tomoregulin con-
centration in Clone36 cells is estimated to be 60 nM, and 120 nM
Figure 2. Equilibrium binding analyses of Tomoregulin by whole
cell binding assay. PC-3, Clone36, and Clone69 cells were incu-
bated with increasing concentrations of 125I-2H8 (from 3.9 pM
to 8 nM) for 3 hours at 4°C in the presence or absence of excess
cold 2H8. The saturation plots of specific binding data are shown
for PC-3 (A), Clone36 (B), and Clone69 (C).
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for Clone69. This information can be useful in choosing cytotoxic
agents with the appropriate potency.
Tomoregulin-Targeted Immunotoxins Selectively Kill Prostate
Cancer Cells
Because 2H8 recognizes Tomoregulin on the cell surface, we tested
whether Tomoregulin is suitable to mediate the delivery of a toxin
by an antibody-based targeting approach. In indirect immunotoxin
experiments, we mixed 2H8 with a goat antimouse IgG antibody
linked to saporin (Mab-ZAP) to preform an antibody–immunotoxin
complex. The 2H8–Mab-ZAP complex induced marked growth
inhibition on Clone69 cells (Figure 6A), which was both time-
and dose-dependent. The IC50 values for the 1:1 mixture of 2H8–
Mab-ZAP on Clone69 cells for the 4, 7, 24, 48, and 72 hours of
incubation were >2.8, 1.9, 0.5, 0.5, and 0.47 nM, respectively,
Figure 4. Internalized Tomoregulin is colocalized with acidic organelles in living cells. Clone69 cells were stained at 4 (A, B, and C) or
37°C (D, E, and F) for Tomoregulin (green in A and D) and for acidic organelles (red in B and E), then fixed, permeabilized, and analyzed by
confocal microscopy. Bars, 10 μm. C and F are merging images of A and B, D and E, respectively. The yellow patches in F indicate
colocalization of the internalized Tomoregulin (green) with acidic organelles (red) at 37°C.
Figure 3. Confocal microscopic analyses of Tomoregulin internalization. Clone36 live cells were incubated with 2H8 for 2 hours at 4°C,
and unbound 2H8 was removed by washes. Cells were then incubated with AlexaFluor 488–labeled antimouse IgG antibody for 3 hours
at 4 (A) or at 37°C (B). After incubation at 37°C, lipid bilayers were stained by CM-DiI red dye (B).
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and the IC50 values found were even lower (0.86, 0.64, 0.19, 0.17,
and 0.16 nM, respectively) with a mixture of 2H8 and fivefold excess
of Mab-ZAP indicating more efficient complex formation. In con-
trast, the complex consisting of the isotype-matched IgG anti–
c-Myc and Mab-ZAP had no effect (IC50 > 3 nM) on Clone69 cell
proliferation even after 72 hours of treatment, indicating that 2H8
targeting is required to initiate cytotoxic killing of Tomoregulin-
positive cells. As expected, 2H8 alone has no growth-inhibitory effect
on Clone69 cells, consistent with our previous observation [7]. Ex-
posure to Mab-ZAP alone served as an additional control and was
also negative (IC50 > 2.6 nM). These results clearly demonstrate that
the 2H8 immunotoxin had a dose- and time-dependent growth
inhibitory effect on the proliferation of Clone69 cells. Also, no
cytotoxic effect was seen with the 2H8–Mab-ZAP complex on
Tomoregulin-negative PC-3 cells (Figure 6B). Again, these results
suggest that the selective cytotoxicity of 2H8 immunotoxin depends
on the surface expression of Tomoregulin on the target cells.
In conclusion, Tomoregulin is an internalizing antigen, and
Tomoregulin-targeted immunotoxins can confer selective cytotoxicity
on Tomoregulin-positive prostate cancer cells but not on Tomoregulin-
negative cells. Hence, Tomoregulin is considered as a promising target
for immunotoxin-based therapy for prostate cancer.
Discussion
Antibodies targeting cell surface tumor antigens represent an
effective way of cancer therapy [16–18]. There are four types of ap-
proved antibody therapeutics: 1) unlabeled antibodies (e.g., Rituxan,
Campath, Herceptin, Avastin, and Erbitux): they kill tumor cells
through mechanisms of apoptosis induction, antibody-dependent
cell-mediated cytotoxicity, and/or complement-dependent cytotoxi-
city; 2) radiolabeled antibodies (e.g., Zevalin, Bexxar): radioimmuno-
Figure 5. Kinetic analyses of Tomoregulin internalization. (A) dis-
tribution of 125I-2H8 when incubating with Clone69 cells at 37°C
at different time points. Curves are as indicated: open circles, cell
surface bound 125I-2H8; open triangles, dissociated 125I-2H8; solid
squares, internalized 125I-2H8. Total radioactivity is set at 100%. (B)
Percent internalization of 125I-2H8 into Clone69 cells over time.
The graph is derived from the data in (A).
Figure 6. Selective cytotoxicity of 2H8 immunotoxin on PC-3–Tomoregulin cells Clone69 (A) but not on Tomoregulin-negative PC-3 cells
(B). Data are expressed as a plot of IC50 values in nanomoles per liter [IC50 (nM)] against the incubation time (hours). Each IC50 value was
determined from a 5-point dose–response curve. Curves are as indicated: filled circles 2H8 alone; open circles, 1:1 complex of 2H8 and
Mab-ZAP; filled triangles, 1:5 complex of 2H8 and Mab-ZAP; open triangles, 1:1 complex of anti–c-Myc and Mab-ZAP; filled squares,
Mab-ZAP alone.
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therapy induces response in patients who are resistant to unlabeled
antibodies, and patients often incur dose-limiting toxicity of radiation
to the bone marrow; 3) antibody–drug conjugates (e.g., Mylotarg):
they cause less nonspecific damage than radiolabeled antibodies but
may not be effective in killing cells that are multidrug-resistant; and
4) immunotoxins (e.g., Ontak): they target tumor cells with consider-
able potency using protein toxins capable of killing a cell with a single
molecule. Ontak (human IL-2 fusion to truncated diphtheria toxin) is
approved for use in cutaneous T-cell lymphoma. Another promising
immunotoxin (an anti-CD22 Fv fusion to truncated Pseudomonas exo-
toxin) has induced complete remissions in high proportion of cases of
hairy-cell leukemia. Development of new immunotoxins are underway
to improve the treatment of cancer [9,10].
The purpose of our study was to explore Tomoregulin-targeted
immunotoxins as a treatment modality for prostate cancer therapy.
We and others have previously demonstrated that Tomoregulin is
expressed by prostate cancer cells in most clinical specimens [7,8].
Among prostate cancer cell lines tested, only LNCaP cells express
the endogenous Tomoregulin mRNA and protein [7]. Because
LNCaP cells in cell cultures express much lower levels of Tomoregulin
protein compared with LNCaP cells in xenograft tumors [7] and
because they form clumps and are difficult to handle, in this study,
we chose to use PC-3 stable cell lines expressing various levels of re-
combinant Tomoregulin protein. These transfected cells (Clone36
and Clone69) had growth rates similar to PC-3 parental cells under
normal growth condition (RPMI-1640 supplemented with 10% FBS;
data not shown) in a 96-hour cell proliferation study using WST-1
reagent. Our results are different from the published data reporting
that overexpression of Tomoregulin inhibits cell proliferation [19].
The opposite results may be due to the different expression levels of
Tomoregulin in these two studies.
The internalization property of Tomoregulin was clearly demon-
strated by confocal microscopy (Figure 3). Here, we used a secondary
antibody to detect Tomoregulin internalization. Does 2H8 internaliza-
tion occur only in the presence of a secondary antibody? To exclude
the effect of the secondary antibody, we also tested AlexaFluor 488–
labeled 2H8 in this assay. We could reproduce the internalization
image except for a much weaker overall signal (data not shown), sug-
gesting that secondary antibody is not essential for Tomoregulin in-
ternalization. We also developed a different assay in which cells were
incubated with 125I-labeled 2H8, and the amount of internalized
antibody was measured by monitoring the radioactivity. Both qualita-
tive (confocal) and quantitative (kinetics) analyses of Tomoregulin in-
ternalization demonstrated that Tomoregulin can rapidly internalize
into cytoplasm on 2H8 binding. Within 90 minutes, the percent of
internalization reached approximately 25%. This internalization per-
centage seems to be constant among the cell lines expressing different
levels of Tomoregulin [Clone69 (Figure 5), Clone36, and Clone15
(data not shown)]. The total number of Tomoregulin internalized in
these cell lines is proportional to the antigen density. Therefore, the
more surface Tomoregulin is present, the more internalization occurs.
Consequently, for a given dose of immunotoxin, its cytotoxicity will
be greater in cells with higher antigen density than those with lower
antigen density.
Two types of receptor internalization have been reported as con-
stitutive internalization versus antibody-induced internalization [20].
Constitutive internalization is the intrinsic property of an antigen,
a permanent receptor turn-over which is independent of antibodies.
In contrast, antibody-induced internalization depends on the proper-
ties of the antibody. The binding affinity and recognition epitope of
the antibody will determine whether the internalization will be in-
duced on binding. In the case of prostate-specific membrane antigen
(PSMA), constitutive internalization has a different rate from that
of antibody-induced internalization. PSMA is constitutively endo-
cytosed in LNCaP cells, and anti-PSMA antibodies increase the rate
of internalization of PSMA [20]. In our study, the internalization of
Tomoregulin on 2H8 binding is detected by AlexaFluor 488–labeled
secondary antibody. We cannot distinguish constitutive internaliza-
tion from antibody-induced internalization for Tomoregulin. When
we tested two additional monoclonal antibodies that bind to epitopes
different from 2H8, Tomoregulin was internalized on the binding
of all antibodies. Thus, it is very likely that Tomoregulin undergoes
constitutive internalization.
A novel internalization motif may be present in the cytoplasmic tail
of Tomoregulin because it does not contain the known motifs that
mediate the internalization of types I and II receptor proteins includ-
ing MXXXL and NPXYYXX* (* is bulky hydrophobic side chain)
[21]. Internalization of PSMA is mediated by the five N-terminal
amino acids (MWNLL) present in its cytoplasmic tail. Deletion of
the cytoplasmic tail abolished PSMA internalization. We searched
for possible internalization motifs in the cytoplasmic domain of
Tomoregulin but have not been successful so far.
Studies have proven that noninternalizing antigens are not as
efficacious as internalizing antigens to deliver toxic agents [22].
The ideal antibodies for delivering immunotoxins are internalizing
antibodies with high tumor accumulation and no or minimal enrich-
ment in essential organs. 2H8 is such an antibody as reported recently
[7]. Here, we demonstrate that a saporin-based 2H8 immunotoxin
specifically binds to Tomoregulin-positive cells and induces a 50%
reduction of viability (IC50) at a concentration of 160 pM when in-
cubated for 72 hours, whereas Tomoregulin-negative cells remain un-
affected. The relative high potency of saporin-based immunotoxins is
not completely understood, although apoptosis induction has been
suggested to contribute [12].
In summary, the 2H8–Mab-ZAP complex is both specific and effec-
tive against Tomoregulin-expressing prostate cancer cells. Direct 2H8–
saporin conjugation and further evaluation of a full human antibody
[23] will show the potential of anti–Tomoregulin-immunotoxin as a
therapeutic agent for prostate cancer.
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